A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Clinical trial NCT04227847 · RECRUITING

Trial details

NCT number: NCT04227847
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Myelodysplastic Syndrome Acute Myeloid Leukemia

Start date: 2020-08-07
Primary completion: 2027-07-04
Enrollment: 178

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.